United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Impact Partnership Wealth LLC

Impact Partnership Wealth LLC grew its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 37.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 974 shares of the biotechnology company’s stock after purchasing an additional 265 shares during the period. Impact Partnership Wealth LLC’s holdings in United Therapeutics were worth $344,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. World Investment Advisors LLC purchased a new position in shares of United Therapeutics during the third quarter valued at approximately $139,206,000. FMR LLC lifted its position in United Therapeutics by 41.1% during the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after buying an additional 314,004 shares during the period. Assetmark Inc. boosted its stake in United Therapeutics by 56.9% in the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock worth $150,492,000 after buying an additional 152,249 shares during the last quarter. Franklin Resources Inc. grew its holdings in United Therapeutics by 97.7% in the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after buying an additional 123,929 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec increased its stake in shares of United Therapeutics by 32.5% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 343,744 shares of the biotechnology company’s stock valued at $123,181,000 after acquiring an additional 84,369 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

UTHR has been the topic of several research analyst reports. HC Wainwright raised their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH upped their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. The Goldman Sachs Group lifted their target price on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. Argus upped their price target on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, TD Cowen raised their price objective on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $378.36.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $370.83 on Friday. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82. The company has a market capitalization of $16.56 billion, a PE ratio of 16.29, a P/E/G ratio of 0.95 and a beta of 0.57. The business has a 50-day moving average of $365.19 and a 200-day moving average of $355.61.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. During the same period in the previous year, the business earned $5.38 EPS. United Therapeutics’s revenue for the quarter was up 22.9% compared to the same quarter last year. On average, equities analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, Director Christopher Causey sold 510 shares of the firm’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $376.63, for a total transaction of $192,081.30. Following the completion of the transaction, the director now directly owns 3,675 shares of the company’s stock, valued at $1,384,115.25. This trade represents a 12.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Paul A. Mahon sold 7,700 shares of the company’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the completion of the sale, the executive vice president now owns 36,710 shares in the company, valued at approximately $13,485,785.60. This trade represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 146,848 shares of company stock worth $55,165,099. Insiders own 11.90% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.